Loading
Nanoplatforms for Cancer Theranostics · Journal article
Exploration · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical report of a novel iron–ruthenium nanozyme designed to modulate tumour microenvironment redox chemistry and enhance anti-PD-L1 immunotherapy. The work demonstrates theoretical catalytic mechanisms and in vitro biochemical activity, but provides no in vivo efficacy data, clinical translation pathway, or quantitative comparison to existing therapies.
Journal article. Intervention: Zero-valent ruthenium-anchored iron-based (FeRu) nanozymes with hollow structure for catalytic redox modulation..
FeRu nanozymes exhibit catalase-like, peroxidase-like, and GSHOx-like activities to generate oxygen and hydroxyl radicals and deplete GSH. Hollow structure design increases exposed catalytic active sites. Density functional theory calculations explain proposed triple catalytic and electron transfer mechanisms.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
In vitro and computational mechanistic work on a novel nanomaterial demonstrates catalytic activity and theoretical potential, but lacks in vivo efficacy data, clinical endpoints, or controlled comparisons to support therapeutic claims.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT The complex tumor microenvironment (TME) includes high concentrations of hydrogen peroxide, high expression of reduced glutathione (GSH), hypoxia, and the resulting immunosuppression from the combination of these features, posing major challenges in tumor therapy. Although nanozymes have demonstrated remarkable potential in treating malignant tumors, nanozymes with zero‐valent metal doping that can simultaneously catalyze the above three indicators to reverse the TME are still limited. Herein, zero‐valent ruthenium was anchored on iron‐based materials to obtain FeRu nanozymes with ruthenium as the “electron bridge” and iron as the “REDOX center” to enhance the electron transfer efficiency. Its hollow structure significantly exposes more catalytic active sites. Density functional theory calculations theoretically explain the potential triple catalytic and electron transfer mechanisms of the nanozyme. The catalase‐like, peroxidase‐like, and GSHOx‐like activities of FeRu nanozymes rapidly generate a large amount of oxygen and hydroxyl radicals, significantly consume GSH, and disrupt the redox balance in tumor cells. These in situ catalytic reactions lead to cell damage, necrosis in malignant tumors, release of damage‐associated molecular patterns, and activation of the adaptive immune response. This work also performs a combined application of anti‐programmed cell death‐ligand 1 and FeRu nanozymes to further enhance the efficacy of immunotherapy, thus providing a new perspective for future cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.